In August, Cantargia presented an update on its CANFOUR clinical trial and phase IIa preparations.
Patents
In July, Cantargia received preliminary approval from EPO for its application for expanded patent protection in respect of the treatment of solid tumours.
In July, Cantargia's patent application for its CAN04 (nidanilimab) antibody was approved in China.
In September, Cantargia's patent application for its CAN04 (nidanilimab) antibody was approved in Japan.
Change of list
In July, Cantargia was approved for listing on Nasdaq Stockholm First North Premier as a preliminary stage in the process of moving to the main list of Nasdaq Stockholm.
In September, Cantargia was approved for listing on the main list of Nasdaq Stockholm with 25 September 2018 as the first day of trading.
Significant events after the end of the period
Cantargia has received a patent for its CAN03 antibody in the US.
In October, Cantargia presented clinical data from its ongoing CANFOUR study at ESMO.
Financial information
First nine months (1 Jan 2018 ? 30 Sep 2018)
Net sales, kSEK 0 (0)
Operating loss, kSEK -65,225 (-45,597)
Loss after tax for the period, kSEK -63,302 (-45,586)
Earnings per share, before and after dilution, SEK -0.96 (-1.48)
Equity/assets ratio, 93 (90) per cent
Cash and cash equivalents, kSEK, 80,691 (32,385)
Short-term investments, kSEK 110,000 (20,000)
Third quarter (1 July 2018 ? 30 Sep 2018)
Net sales, kSEK 0 (0) KSEK
Operating loss, kSEK -21,412 (-11,306)
Loss after tax for the period, kSEK -21,456 (-11,306)
Earnings per share, before and after dilution, SEK -0.32 (-0.35)
For further information, please contact Göran Forsberg, CEO Telephone: +46(0)46-275-62-60 E-mail: [email protected]
This is information that Cantargia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on November 15 2018.
About us Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases. The basis for this is the protein IL1RAP that is involved in a number of diseases and where Cantargia has established a platform. The main project, the antibody CAN04 (nidanilimab) is being studied in the clinical phase I/IIa CANFOUR with a primary focus on non-small cell lung cancer and pancreatic cancer. The study is conducting both monotherapy and combination therapy. Cantargia's other project, CANxx, is in the research phase and is aiming to develop a IL1RAP binding antibody optimised for the treatment of autoimmune and inflammatory diseases.
Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at http://www.cantargia.com.
Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patientsGastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a rare cancer that...
Jesse Patterson has always been more of a self-treatment type of guy when it comes to dealing with his health. So, when the normally active 73-year-old New Holland resident started getting short of breath and felt his lungs burning when he walked any...
Empowered by employee donations and matched by management contributions, Radians® quarterly Tickets for Charity (TFC) program champions local Memphis and Midsouth charities, offering crucial support for sustaining daily operations and expanding their...
Multi-award-winning Civil Rights Attorney and Child Advocate, Areva Martin, in collaboration with the Special Needs Network (SNN), has revealed the distinguished honorees for the 16th Annual A Pink Pump Affair. This noteworthy charity event is...
Convergent Dental, the power behind the Solea® All-Tissue Dental Laser, proudly announces the rebranding of its annual customer event from the "Solea User Group Meeting" to the "Solea Summit." This update reflects the evolution of the event into the...
The Laniado Hospital in Netanya, Israel, is embarking on a crucial initiative to construct the country's first fully sheltered emergency care building. With the support of the Laniado Development Fund, this endeavor aims to enhance public healthcare...